Related Experiment Video
Updated: May 19, 2026

Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture
Published on: February 11, 2019
RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas
Aphrothiti J Hanrahan1, David B Solit
1Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA.
Abstract:
Studies using genetically engineered mouse models indicate that RAF activation is sufficient to induce pancreatic intraepithelial neoplasms, suggesting that mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor-based combination approaches may have clinical use in patients with pancreatic ductal adenocarcinomas.
Insights
RAF activation can cause pancreatic tumors in mice. This suggests that combining MEK inhibitors with other treatments may help patients with pancreatic cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- RAF activation is a key event in various cancers.
- Pancreatic intraepithelial neoplasms (PanINs) are precursors to pancreatic ductal adenocarcinomas (PDAC).
- The role of RAF-MAPK signaling in PDAC development is under investigation.
Purpose of the Study:
- To investigate the role of RAF activation in the development of pancreatic intraepithelial neoplasms.
- To explore the potential of targeting the MAPK/ERK pathway in PDAC treatment.
Main Methods:
- Utilized genetically engineered mouse models (GEMMs) to study pancreatic carcinogenesis.
- Analyzed the induction of pancreatic intraepithelial neoplasms upon RAF activation.
Main Results:
- RAF activation was found to be sufficient for inducing pancreatic intraepithelial neoplasms in mouse models.
- This provides evidence for the oncogenic role of RAF signaling in pancreatic cancer initiation.
Conclusions:
- RAF-driven signaling is a critical factor in pancreatic cancer development.
- Combination therapies involving mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitors may offer a promising therapeutic strategy for pancreatic ductal adenocarcinomas.

